Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Greimel, E; Bjelic-Radisic, V; Nagele, E; Bliem, B; Tamussino, K.
Quality of life in patients with ovarian cancer
ONKOLOGE. 2019; 25(2): 151-156. Doi: 10.1007/s00761-018-0484-y
Web of Science FullText FullText_MUG

Leading authors Med Uni Graz: Greimel Elfriede Renate
Co-authors Med Uni Graz: Bjelic-Radisic Vesna; Bliem Brigitte; Nagele Eva Helene; Tamussino Karl
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Progress in surgical and systemic treatment for ovarian cancer has prolonged survival times of patients and changed the focus towards patients' quality of life (QoL). The inclusion of patient-reported outcomes (PROs) as primary or secondary outcomes in clinical ovarian cancer studies has significantly increased in recent years. There are standardized instruments developed specifically for ovarian cancer patients to measure PROs. Web-based ePRO questionnaires are also available, saving time and expense. Results from clinical studies with PROs as the focus have led to a change in the international standardized therapy for ovarian cancer. Based on these data carboplatin/paclitaxel has become the new worldwide standard primary therapy for advanced ovarian cancer. A further individualization of treatment taking QoL of patients into account, could be made possible for late relapsed ovarian cancer. In addition to clinical trials, PROs are increasingly being used in routine clinical practice. The majority of cancer patients support the routine assessment of QoL. The PRO data provide important information about the subjective effect of the disease and the treatment on the QoL of patients. This information can then be used for clinical decision-making to select the best treatment option based on the needs of the patients.
Find related publications in this database (Keywords): Gynecological tumors; Patient-reported outcomes; Chemotherapy; Clinical trials; Quality of life